Top Stories
-
Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Topic
-
Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
Topic
-
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Topic
-
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Topic
Latest News
- January 27, 2016
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer.
Topic
- January 20, 2016
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
Topic
- January 19, 2016
A new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears to have fewer side effects than a previous therapy.
- October 29, 2015
Columbia researchers Andrea Califano and Jean Gautier have received prestigious NCI awards that support and encourage leaders in cancer research.
Topic
- October 28, 2015
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
Topic
- October 26, 2015
Dr. Andrea Califano has won a two-year $200,000 research grant for neuroendocrine cancer research.
Topic
- October 21, 2015
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
Topic
- October 12, 2015
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
Topic
- October 5, 2015
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
Topic
- September 23, 2015
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Topic
